Oxford Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Oxford Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-93,589	Closed	-$62K	–	2044
2019 Q1	$62K	Buy	93,589 +36,534	+64%	+$44.7K	﹤0.01%	1593
2018 Q4	$98K	Buy	+57,055	New	+$171K	﹤0.01%	1650
2018 Q1	–	Sell	-22,097	Closed	-$165K	–	1979
2017 Q4	$165K	Buy	+22,097	New	+$183K	﹤0.01%	1479
2017 Q1	–	Sell	-24,660	Closed	-$139K	–	1517
2016 Q4	$139K	Buy	24,660 +7,967	+48%	+$79.3K	﹤0.01%	723
2016 Q3	$247K	Sell	16,693 -78,574	-82%	-$905K	0.01%	687
2016 Q2	$855K	Sell	95,267 -52,552	-36%	-$546K	0.03%	514
2016 Q1	$1.37M	Buy	+147,819	New	+$1.25M	0.04%	433

Other funds holding TRIL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Oxford Asset Management's TRIL Position: Q2 2019 in Review

Oxford Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2019, closing a stake of 93,589 shares — an estimated $62K sold.

Oxford Asset Management first reported a position in TRIL in Q1 2016 and held it in 7 quarters. The position peaked at $1.37M in Q1 2016. 19 funds tracked by Wall St. Rank hold TRIL as of Q2 2019.

Oxford Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q2 2019 after selling out during the quarter.
Oxford Asset Management sold 93,589 Trillium Therapeutics Inc. shares in Q2 2019, an estimated $62K.
Oxford Asset Management first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 7 quarters.
Oxford Asset Management's Trillium Therapeutics Inc. position peaked at $1.37M in Q1 2016.
19 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2019.

Based on Oxford Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.